GTC
ACHN

Ghost Tree Capital’s Achillion Pharmaceuticals ACHN Stock Holding History

Ghost Tree Capital’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-150,000
Closed -$1.84M – 86
2014
Q4 		$1.84M Hold
150,000
– – 0.88% 44
2014
Q3 		$1.5M Hold
150,000
– – 0.81% 47
2014
Q2 		$1.14M Buy
+150,000
New +$599K 0.8% 37

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ghost Tree Capital's ACHN Position: Q2 2016 in Review

Ghost Tree Capital sold out of Achillion Pharmaceuticals (ACHN) in Q2 2016, closing a stake of 250,000 shares — an estimated $1.93M sold.

Ghost Tree Capital first reported a position in ACHN in Q1 2015 and held it in 4 quarters. The position peaked at $6.47M in Q4 2015. 147 funds tracked by Wall St. Rank hold ACHN as of Q2 2016.

  • Ghost Tree Capital reported no remaining Achillion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Ghost Tree Capital sold 250,000 Achillion Pharmaceuticals shares in Q2 2016, an estimated $1.93M.
  • Ghost Tree Capital first reported a position in Achillion Pharmaceuticals in Q1 2015 and held it in 4 quarters.
  • Ghost Tree Capital's Achillion Pharmaceuticals position peaked at $6.47M in Q4 2015.
  • 147 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q2 2016.

Based on Ghost Tree Capital's 13F filing for Q2 2016, filed 12 Aug 2016.